PharmNXT Bets on DTR Integration to Drive Global Biotech Growth

Mumbai-based biotech startup PharmNXT Biotech is positioning itself for global expansion following the integration of Ireland-based Defined Tubing Routing (DTR), an acquisition announced in mid-2025 that strengthens its bioprocess engineering capabilities.

The integration provides PharmNXT with access to GMP-compliant modular tubing technology capable of managing process volumes from 20 liters to 2,000 liters, with customized spans of up to 2.9 meters. The color-coded routing system enhances operator safety, reduces human error, and enables faster, more flexible biomanufacturing facility setups.

“The DTR integration also expands our engineering capacity to deliver higher customization, improved flow consistency, and greater compliance,” said Ankush Kapoor, founder and CEO, PharmNXT.

“This acquisition is our gateway to the global market. By integrating DTR’s existing international clientele with our capabilities, PharmNXT now has direct access to new customers and ecosystems. This creates an immediate opportunity to expand into high-growth markets such as South Korea and Europe, where demand for advanced biomanufacturing solutions is rising. Equally important, the products we design and manufacture in India can now be promoted through DTR’s global network,” he added.

While the company has been growing organically, Kapoor said inorganic expansion is critical for innovation and global knowledge transfer. He noted that PharmNXT is self-reliant in funding but remains open to strategic investments that offer global market access.